No Data
No Data
No Data
No Data
No Data
Wedbush: Reiterates the Adicet Bio (ACET.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
Wedbush: Reiterates the Adicet Bio (ACET.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
Zhitong FinanceApr 24 00:30
Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:ACET) with a Outperform and maintains $5 price target.
BenzingaApr 24 00:29
Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data
TipRanksApr 23 04:42
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor
BusinesswireApr 23 04:30
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
BusinesswireApr 8 19:00
Adicet Bio Is Maintained at Buy by HC Wainwright & Co.
Adicet Bio Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 2 20:51
No Data
No Data